GFAP and Alzheimer disease: It has been shown that Se-Met significantly reduced both GFAP and CD45 immunoreactivity in the OB of 3× Tg-AD mice compared with the control mice (CD45: p < 0.01; GFAP: p < 0.05; Figure 5A,B).